首页> 外文会议>Materials Research Society Meeting >CPT Encapsulated Silica-titania Hollow Nanoparticle Targeting SK-BR-3 Cells for efficient Anticancer treatment
【24h】

CPT Encapsulated Silica-titania Hollow Nanoparticle Targeting SK-BR-3 Cells for efficient Anticancer treatment

机译:CPT封装的二氧化硅 - 二氧化钛中空纳米粒子靶向SK-BR-3细胞,用于有效的抗癌治疗

获取原文

摘要

HER-conjugated hollow nanoparticles (HER-HNP, ca. 50 nm in diameter) are fabricated using a dissolution and re-deposition method and used to encapsulate camptothecin (CPT). The HER-HNP-CPT is used as an anti-cancer agent for human breast cancer SK-BR-3. It has excellent mono-dispersity and a high loading efficiency for CPT. Two kind of cell lines are used in this study; SK-BR-3 and RAW 264.7. SK-BR-3 and RAW 264.7 are used as targeting and controlling cell line, respectively. When SK-BR-3 cells are treated with HER-HNP-CPT, the viability decreased to 55%, which is ca. 1.5 times higher anti-cancer efficiency in comparison to RAW 264.7. The HER-HNP-CPT system offers a new opportunity to facilitate implementation of a hydrophobic drug for effective anti-cancer treatment of SK-BR-3 cells.
机译:使用溶解和再沉积方法制造她缀合的中空纳米颗粒(Inder-HNP,CA.50nm,直径50nm),并用于包封Camptothecin(CPT)。 HER-HNP-CPT用作人乳腺癌SK-BR-3的抗癌剂。它具有优异的单分散性和CPT的高负载效率。本研究使用两种细胞系; SK-BR-3和RAW 264.7。 SK-BR-3和RAW 264.7分别用作靶向和控制细胞系。当用HER-HNP-CPT处理SK-BR-3细胞时,活力降低至55%,即为CA。与RAW 264.7相比,抗癌效率较高1.5倍。 Hy-HNP-CPT系统提供了一种新的机会,可促进实施疏水性药物,以实现SK-BR-3细胞的有效抗癌治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号